Friday, October 23, 2026
23.2 C
Bengaluru

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business unit. It was a scientific outpost.

I entered this field when we measured success by the depth of a clinical conversation, not the breadth of a CRM dashboard. Today, oncology is a multi-billion-dollar strategic chess match. But as we have gained scale, there is a lingering question: have we lost the plot?

Looking back at four decades from the frontlines, the evolution of cancer care in India was not a slow climb. It was a series of radical rewiring events that changed how we think, sell, and treat.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

China’s Biopharma Strategy: A Warning and Opportunity for India

China is playing a long game in biopharma. And...

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy,...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Topics

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of...
spot_img

Related Articles

spot_imgspot_img